focus -WSS

focus

author：knowledge 2025-08-12 09:11:29 - browse：15

Adobe

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available a novel treatment for a deadly condition that’s long been challenging to treat.

In a large trial published last year, the drug, called sotatercept, exceeded expectations in significantly increasing the distance that patients could walk and cutting the risk that their condition would worsen, that they would die, and that they would need new treatments.

Pulmonary arterial hypertension, or PAH, is estimated to occur in 15 to 50 per million people, mostly in women. It’s characterized by a proliferation of cells in the blood vessels that connect the right side of heart to the lungs, making it harder for blood to pass through and leading the heart to have to work harder to pump blood into the lungs. The disease, which causes difficulty breathing, fatigue and dizziness, has a high mortality rate, with one study finding that one-fifth of patients died at around three years after diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： J&J expands global access to TB drug amid advocacy campaign

Wikipedia

explore

WSS

Ebola vaccine can save some who are already sick, per new study

Eli Lilly reports tirzepatide MASH success during Q4 earnings

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Juul documents reveal insider tactics on political lobbying

AMAs digital advisors table RPM coding reform proposal, again

leisure time

focus

focus

Duchenne breakthrough therapy leaves behind pioneering families

Report cites 'urgent' need to recruit more diverse clinical trial participants

What does generative AI mean for health care? We asked experts

Why don't Americans have at

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Tome Biosciences co

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Medicare details structure of new drug price negotiation program

Artificial intelligence use in health care faces greater scrutiny in 2024

hotspot

Doctors on social media are being harassed and cyberbullied

Too many hospitalized Covid

Too many hospitalized Covid

Too many hospitalized Covid

Too many hospitalized Covid

Too many hospitalized Covid

leisure time

Wikipedia

explore

explore